About Index Trending news
Analyze
Pricing
ArGEN-X

ArGEN-X

ArGEN-X

arGENX is a clinicalstage biopharmaceutical company focused on creating and developing differentiated therapeutic antibodies for the treatment of cancer and severe autoimmune diseases.

Elsewhere

Alexa global traffic share

03 Jun 2016
€30,000,000
Post-IPO equity
MPM Capital, Dafna Capital Management, Burrage Capital, +1

argenx successfully closes €30 million private placement

BioPortfolio
02 Dec 2011
€32
Venture capital (Series B)
Added by